Your browser doesn't support javascript.
loading
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.
O'Connell, Casey L; Baer, Maria R; Ørskov, Andreas Due; Saini, Sunil Kumar; Duong, Vu H; Kropf, Patricia; Hansen, Jakob Werner; Tsao-Wei, Denice; Jang, Hyo Sik; Emadi, Ashkan; Holmberg-Thyden, Staffan; Cowland, Jack; Brinker, Brett T; Horwood, Kristin; Burgos, Ryan; Hostetter, Galen; Youngblood, Benjamin A; Hadrup, Sine Reker; Issa, Jean-Pierre; Jones, Peter; Baylin, Stephen B; Siddiqi, Imran; Grønbaek, Kirsten.
Afiliação
  • O'Connell CL; Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Baer MR; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
  • Ørskov AD; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Saini SK; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Duong VH; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Kropf P; The Danish Stem Cell Center (Danstem), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Hansen JW; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Tsao-Wei D; Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Jang HS; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
  • Emadi A; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Holmberg-Thyden S; Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Cowland J; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
  • Brinker BT; Biotech Research and Innovation Centre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Horwood K; The Danish Stem Cell Center (Danstem), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Burgos R; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Hostetter G; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Youngblood BA; Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
  • Hadrup SR; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland.
  • Issa JP; Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Jones P; Department of Clinical Genetics, Rigshospitalet, Copenhagen, Denmark.
  • Baylin SB; Medical Oncology, Cancer and Hematology Centers of West Michigan, Grand Rapids, Michigan.
  • Siddiqi I; Jane Anne Nohl Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Grønbaek K; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
Clin Cancer Res ; 28(24): 5306-5316, 2022 12 15.
Article em En | MEDLINE | ID: mdl-36222848

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mielomonocítica Crônica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Leucemia Mielomonocítica Crônica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article